Bio & Pharma
Daewoong wins permission for Nabota in Argentina
The S.Korean drugmaker plans to release its botulinum toxin product through the distribution channels of the local firm
By Jul 15, 2024 (Gmt+09:00)
1
Min read
Most Read
S.Korea's LS Materials set to boost earnings ahead of IPO process
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
Gas maker Air Products Korea put on sale for around $3.6 bn
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
K-content powerhouse’s YouTube channels disrupted by hacks
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
Mercedes, BMW, Audi, VW offer deep discounts amid EV phobia in Korea
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
Carlyle, Keppel, IMM stay in final race for Ecorbit
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
![Daewoong wins permission for Nabota in Argentina](https://www.kedglobal.com/data/ked/image/2024/07/15/ked202407150014.647x.0.jpg)
South Korea's Daewoong Pharmaceutical Co. announced on Monday that its botulinum toxin Nabota received product approval from Argentina's National Administration of Drugs, Food and Medical Technology (ANMAT) last month.
The Argentine name is Clodew.
Daewoong plans to launch Clodew in Argentina through its local partner Oxapharma in the fourth quarter of this year and will actively engage in brand marketing.
Daewoong explained that this is the first time a domestically produced botox has received product approval in Argentina.
According to Daewoong Pharmaceutical, Argentina is an attractive market, ranking fourth for the average number of botox procedures per capita last year.
However, the company said that entering the market is challenging due to high entry barriers, such as the requirement for Good Manufacturing Practice (GMP) certification from high-surveillance countries recognized by the Argentine government, including the US and Europe.
Write to Young-ae Lee at 0ae@hankyung.com
More to Read
-
Bio & PharmaDaewoong, Indonesia's IPB to co-research on primate
Jun 27, 2024 (Gmt+09:00)
1 Min read -
Bio & PharmaDaewoong Pharmaceutical digitizes DB of 800 mn chemical compounds
Feb 19, 2024 (Gmt+09:00)
1 Min read -
Bio & PharmaDaewoong gets stem cell facility license in Indonesia
Feb 13, 2024 (Gmt+09:00)
1 Min read -
Bio & PharmaDaewoong exports $92.4 mn Depot injection tech to UAE
Dec 11, 2023 (Gmt+09:00)
1 Min read -
Bio & PharmaDaewoong Pharma's GER drug gets product OK from Mexico
Oct 19, 2023 (Gmt+09:00)
1 Min read
Comment 0
LOG IN